Skip to main content

Published locations for First-line obinutuzumab monotherapy in CLL linked to good response, reduced toxicity

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. First-line obinutuzumab monotherapy in CLL linked to good response, reduced toxicity

User login

  • Reset your password
  • /content/first-line-obinutuzumab-monotherapy-cll-linked-good-response-reduced-toxicity
  • /hematologynews/article/142463/cll/first-line-obinutuzumab-monotherapy-cll-linked-good-response
  • /oncologypractice/article/142463/cll/first-line-obinutuzumab-monotherapy-cll-linked-good-response
  • /hematology-oncology/article/142463/cll/first-line-obinutuzumab-monotherapy-cll-linked-good-response
  • /b-cell-lymphoma-icymi/article/142463/cll/first-line-obinutuzumab-monotherapy-cll-linked-good